Ophthalmic Surgery, Lasers and Imaging Retina

Images in Ophthalmology 

Pigmented Ocular Fundus Lesions Associated With Familial Adenomatous Polyposis

Chris J. Li, BS; Antonio Yaghy, MD; Carol L. Shields, MD

Abstract

A 36-year-old man was referred for evaluation after trauma to the left eye. He gave a history of familial adenomatous polyposis (FAP) diagnosed at age 15 years and treated with prophylactic colectomy. Funduscopy revealed multifocal pigmented ocular fundus lesions at the level of the retinal pigment epithelium (RPE) in both eyes (Figure 1A and 1B). The lesions were haphazardly distributed, oval-shaped, variable in size, and with irregular borders. On fundus autofluorescence, the RPE lesions were hypoautofluorescent and surrounded by trace hyperautofluorescence (Figure 1C and 1D). These findings represented the pigmented ocular fundus lesions that serve as a biomarker for FAP.

[Ophthalmic Surg Lasers Imaging Retina. 2020;51:124.]

Abstract

A 36-year-old man was referred for evaluation after trauma to the left eye. He gave a history of familial adenomatous polyposis (FAP) diagnosed at age 15 years and treated with prophylactic colectomy. Funduscopy revealed multifocal pigmented ocular fundus lesions at the level of the retinal pigment epithelium (RPE) in both eyes (Figure 1A and 1B). The lesions were haphazardly distributed, oval-shaped, variable in size, and with irregular borders. On fundus autofluorescence, the RPE lesions were hypoautofluorescent and surrounded by trace hyperautofluorescence (Figure 1C and 1D). These findings represented the pigmented ocular fundus lesions that serve as a biomarker for FAP.

[Ophthalmic Surg Lasers Imaging Retina. 2020;51:124.]

Authors

From the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia.

Support provided in part by the Eye Tumor Research Foundation, Philadelphia, PA (CLS). The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. Dr. Shields has had full access to all the data in the study and takes responsibility for the integrity of the data.

The authors report no relevant financial disclosures.

Address correspondence to Carol L. Shields, MD, Ocular Oncology Service, 840 Walnut Street, Suite 1440, Philadelphia, PA 19107; email: carolshields@gmail.com.

Received: August 28, 2019
Accepted: October 29, 2019

10.3928/23258160-20200129-10

Sign up to receive

Journal E-contents